Literature DB >> 6769122

In vivo or in vitro treatments with anti-I-J alloantisera abolish immunity to AKR leukemia.

D Meruelo, N Flieger, D Smith, H O McDevitt.   

Abstract

This paper provides evidence for the involvement of immune mechanisms in conferring resistance to a spontaneous AKR leukemia. It is shown that genes in the B, J, or E subregions of the H-2 complex confer resistance to a spontaneously arisen, tissue culture-adapted AKR thymoma, BW5147. A direct correlation is demonstrated between survival to injected BW5147 cells and humoral responsiveness in various hybrids obtained from crosses of AKR mice and C57BL/10 or C3H/DiSn derived congeneic strains differing at H-2. Cellular immunity appears to play no role in resistance to the proliferation of tumor cells. It is further established that development of effective humoral immunity depends on B cells and Ly-1+, 2-, 3- helper T-cells bearing the I-Jk phenotype. These findings seem directly applicable to the spontaneous disease, and results of studies using transformed cells from an overtly leukemic AKR mouse parallel those obtained using BW1547 cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769122      PMCID: PMC348675          DOI: 10.1073/pnas.77.4.2178

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  SPECIFICITY OF ISOANTISERA AGAINST LEUKAEMIC AND THYMIC LYMPHOCYTES.

Authors:  A E REIF; J M ALLEN
Journal:  Nature       Date:  1963-12-28       Impact factor: 49.962

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

Review 3.  Recent studies on the role of the immune response in resistance to virus-induced leukemias and lymphomas.

Authors:  D Meruelo; H O McDevitt
Journal:  Semin Hematol       Date:  1978-10       Impact factor: 3.851

Review 4.  Protein clinical manifestations of primary tumors of the heart.

Authors:  H O McDevitt; W F Bodmer
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

5.  The role of genetics in Gross virus leukemogenesis.

Authors:  F Lilly
Journal:  Bibl Haematol       Date:  1970

6.  Reduction of syngeneic tumor growth by an anti-I-J-alloantiserum.

Authors:  M I Greene; M E Dorf; M Pierres; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

7.  Assessing B cell diversification by antigen receptor and precursor cell analysis.

Authors:  N R Klinman; A R Pickard; N H Sigal; P J Gearhart; E S Metcalf; S K Pierce
Journal:  Ann Immunol (Paris)       Date:  1976 Jun-Jul

8.  Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. IV. Special subregion assignment of the gene(s) that codes for the suppressive T-cell factor in the H-2 histocompatibility complex.

Authors:  T Tada; M Taniguchi; C S David
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

9.  Increased synthesis and expression of H-2 antigens on thymocytes as a result of radiation leukemia virus infection: a possible mechanism for H-2 linked control of virus-induced neoplasia.

Authors:  D Meruelo; S H Nimelstein; P P Jones; M Lieberman; H O McDevitt
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

10.  Genetic control of cell-mediated responsiveness to an AKR tumor-associated antigen: mapping of the locus involved to the I region of the H-2 complex.

Authors:  D Meruelo; B Deak; H O McDevitt
Journal:  J Exp Med       Date:  1977-11-01       Impact factor: 14.307

View more
  14 in total

1.  Ly-1 inducer and Ly-1,2 acceptor T cells in the feedback suppression circuit bear an I-J-subregion controlled determinant.

Authors:  D D Eardley; D B Murphy; J D Kemp; F W Shen; H Cantor; R K Gershon
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

Review 2.  The role of contrasuppression in tumor regression.

Authors:  P M Flood; A Friedman; J Freedman; B Horvat; P Reuter; W Ptak
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

3.  Analysis of H-2-linked immune responses involved in resistance to AKR tumor growth.

Authors:  M A Zalman; D Meruelo
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

4.  The use of a monoclonal i-j-specific antibody to distinguish cells in the feedback suppression circuit from those in the contrasuppressor circuit.

Authors:  K Yamauchi; M Taniguchi; D Green; R K Gershon
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

Review 5.  I-J subregion and suppressor signals.

Authors:  J S Bromberg; A Tominaga; M Takaoki; M I Greene
Journal:  Surv Immunol Res       Date:  1982

6.  In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor.

Authors:  M K Waldor; S Sriram; H O McDevitt; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

Review 7.  Regulation of the immune response to antigens on the malignant cell surface.

Authors:  J A Drebin; L L Perry; R Carter; M I Greene
Journal:  Springer Semin Immunopathol       Date:  1982

8.  In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis.

Authors:  L Steinman; J T Rosenbaum; S Sriram; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

9.  In vivo effects of antibodies to immune response gene products. I. Haplotype-specific suppression of humoral immune responses with a monoclonal anti-I-A.

Authors:  J T Rosenbaum; N E Adelman; H O McDevitt
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

10.  Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.

Authors:  N E Adelman; D L Watling; H O McDevitt
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.